Is active acid sphingomyelinase required for the antiproliferative response to rituximab?

Blood. 2011 Mar 31;117(13):3695-6. doi: 10.1182/blood-2010-11-318493.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Antibodies, Monoclonal, Murine-Derived / administration & dosage
  • Antibodies, Monoclonal, Murine-Derived / pharmacology*
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Cell Proliferation / drug effects*
  • Cyclophosphamide / administration & dosage
  • Drug Resistance, Neoplasm / drug effects
  • Drug Resistance, Neoplasm / genetics*
  • Humans
  • Lymphoma, B-Cell, Marginal Zone / drug therapy
  • Lymphoma, B-Cell, Marginal Zone / genetics
  • Male
  • Prednisone / administration & dosage
  • Rituximab
  • Sphingomyelin Phosphodiesterase / deficiency
  • Sphingomyelin Phosphodiesterase / genetics
  • Sphingomyelin Phosphodiesterase / metabolism
  • Sphingomyelin Phosphodiesterase / physiology*
  • Treatment Failure
  • Vincristine / administration & dosage

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents
  • Rituximab
  • Vincristine
  • Cyclophosphamide
  • SMPD1 protein, human
  • Sphingomyelin Phosphodiesterase
  • Prednisone